We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Next-Generation Whole-Cell Biosensors May Provide New Approach to Diagnostics

By LabMedica International staff writers
Posted on 08 Jun 2015
Print article
Image: Newly designed bacteria with synthetically rewired genetic circuitry act as bactosensors to detect abnormal glucose levels in urine of diabetes patients (Photo courtesy of Chris Bickel and the journal Science).
Image: Newly designed bacteria with synthetically rewired genetic circuitry act as bactosensors to detect abnormal glucose levels in urine of diabetes patients (Photo courtesy of Chris Bickel and the journal Science).
Image: Illustration of principle for using modified, “programmed” bacteria as “bactodetectors” of molecular markers for medical diagnosis (Photo courtesy of J. Bonnet and INSERM).
Image: Illustration of principle for using modified, “programmed” bacteria as “bactodetectors” of molecular markers for medical diagnosis (Photo courtesy of J. Bonnet and INSERM).
Researchers have developed the first programmable bacterial cells for medical diagnosis with improved computing and amplification capacity that could enable earlier clinical detection of various pathological biomarkers in urine or blood.

Several hurdles have limited the application of whole-cell biosensors as analytical clinical tools, primarily their unreliable operation in complex samples and low signal-to-noise ratio. Teams led by Jerome Bonnet (INSERM, CNRS; Montpellier University; Montpellier, France), Franck Molina (SysDiag, CNRS; Montpellier, France), in association with teams led by Eric Renard (Montpellier Regional University Hospital; Montpellier, France) and Drew Endy (Stanford University; Standford, CA, USA), have transformed bacteria into diagnostic agents by inserting the equivalent of a computer program into their DNA. These “bactosensors” with genetically encoded digital amplifying genetic switches can detect clinically relevant molecular markers. They perform signal digitization and amplification, multiplexed signal processing via Boolean logic gates, and data storage.

In vitro diagnostic (IVD) tests are generally noninvasive and simple, but some are complex, requiring sophisticated technologies often available only in central laboratories. Living cells can detect, process, and respond to many signals. Provided with an appropriate “program” they can accomplish diagnostic tasks. To do this, Jerome Bonnet’s team at had the idea to apply concepts from synthetic biology derived from electronics to construct genetic systems to “program” living cells like a computer.

As a central component of modern electronic instruments (including calculators and smartphones), the transistor acts both as a switch and a signal amplifier. In informatics, several transistors are combined to construct “logic gates” that respond to different signal combinations according to a predetermined logic. For example, a dual input “AND” logic gate will produce a signal only if both of two input signals are present. At Standford University Jerome Bonnet had previously invented a genetic transistor named the “transcriptor.” Inserting transcriptors into bacteria can transform them into calculators, where electrical signals used in electronics are replaced by molecular signals that control gene expression. It is thus possible to reprogram the cells by implanting simple genetic “programs” as sensor modules that enable cells to respond to specific combinations of molecules.

The team now applied this new technology to detect disease “signals” in clinical samples. The transcriptor amplification ability was used to detect biomarkers even at very small amounts, and the test results were successfully stored in the bacterial DNA for several months. Thus, the semi-synthetic cells acquired the ability to perform different functions based on the presence of several markers, opening the way to more accurate diagnostic tests that rely on detection of molecular “signatures” using different biomarkers.

As a proof-of-concept clinical experiment, the transcriptor was connected to a bacterial system that responds to glucose and successfully detected the abnormal levels of glucose in urine of diabetic patients.

“We have standardized our method, and confirmed the robustness of our synthetic bacterial systems in clinical samples. We have also developed a rapid technique for connecting the transcriptor to new detection systems. All this should make it easier to reuse our system,” said first author Alexis Courbet, “Our work is presently focused on the engineering of artificial genetic systems that can be modified on demand to detect different molecular disease markers,” said Jerome Bonnet.

The study, by Courbet A, et al., was published May 27, 2015, in the journal Science Translational Medicine.

Related Links:

INSERM 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.